A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET
Treatment Preferences for Somatuline® Injector Devices: A Discrete Choice Experiment (DCE) of Patients With Neuroendocrine Tumors (NETs) and Nurses in the United States (US) and Canada
Sponsor: Ipsen
Terminated
Significant and complex challenges had since been identified during recent testing phases. After their assessment, Ipsendecided to discontinue development of this motorized device in order to not burden participants.
Other terminated trials from Ipsen
This observational or N/A phase trial investigates Neuroendocrine Tumors and is currently terminated or withdrawn. Ipsen leads this study, which shows 9 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Mar 2024 — Jul 2024 [monthly]
Terminated
Status: Recruiting → Terminated
-
Jan 2024 — Mar 2024 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Nov 2023 — Jan 2024 [monthly]
Recruiting
-
Sep 2023 — Nov 2023 [monthly]
Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Not Yet Recruiting
First recorded
Jun 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .